Literature DB >> 886463

Pharmaceutical applications of solid dispersion systems: X-ray diffraction and aqueous solubility studies on griseofulvin-polyethylene glycol 6000 systems.

W L Chiou.   

Abstract

The X-ray diffraction method was used to characterize physiochemical properties of griseofulvin dispersed in polyethylene glycol 4000 and 6000. Results indicate a negligible or very limited solid solubility of griseofulvin in the pulverized solid dispersions. Pulverization and aging had pronounced effects on the X-ray diffraction spectrum. Results from aqueous solubility studies of griseofulvin in various concentrations of polyethylene glycol 6000 further indicate weak or insignificant interactions between the drug and the carrier. Mechanisms are postulated to account for the reported marked enhancement of dissolution rates and oral adsorption of griseofulvin dispersed in these carriers.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 886463     DOI: 10.1002/jps.2600660722

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

1.  Phase behavior of amorphous molecular dispersions II: Role of hydrogen bonding in solid solubility and phase separation kinetics.

Authors:  Madhav Vasanthavada; Wei-Qin Tong; Yatindra Joshi; M Serpil Kislalioglu
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

2.  Solid surfactant solutions of active ingredients in sugar esters.

Authors:  L Hahn; H Sucker
Journal:  Pharm Res       Date:  1989-11       Impact factor: 4.200

3.  Influence of solvent mixtures on HPMCAS-celecoxib microparticles prepared by electrospraying.

Authors:  Adam Bohr; Yingya Wang; Moritz Beck-Broichsitter; Mingshi Yang
Journal:  Asian J Pharm Sci       Date:  2018-03-12       Impact factor: 6.598

4.  Improvement of solubility and dissolution properties of clotrimazole by solid dispersions and inclusion complexes.

Authors:  Gehan Balata; M Mahdi; Rania Abu Bakera
Journal:  Indian J Pharm Sci       Date:  2011-09       Impact factor: 0.975

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.